Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Recruiting 2Approved for marketing 2Active not recruiting 2Withdrawn 1Unknown 1Terminated 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Hepatocellular 7Neoplasms 2Urologic Neoplasms 1Thyroid Neoplasms 1Sarcoma, Kaposi 1Hepatitis B 1GBM 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1Advanced Hepatocellular Carcinoma 1Acrocephalosyndactylia 1

Interventions

vandetanib 1pembrolizumab 1lenvatinib 1fosbretabulin 1fludarabine 1combretastatin 1aldesleukin 1Water 1Thyroxine 1Thyrotropin-Releasing Hormone 1Tea 1Paclitaxel 1Milk 1Iodine-124 1Iodine-123 1Fluorodeoxyglucose F18 1Drug Therapy 1Docetaxel 1DNA 1Cyclophosphamide 1Coffee 1Carboplatin 1Biopsy, Fine-Needle 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Thyroid Neoplasms × lenvatinib × Clear all
NCT04731740 2024-03-25

Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer

Saint Petersburg State University, Russia

Phase 2 Withdrawn
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡